{"url_path":"/sec/pvla/8-k/2026-05-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001193125-26-232717-index.html","accession_number":"0001193125-26-232717","cik":"0001583648","ticker":"PVLA","issuer_name":"PALVELLA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001193125-26-232717-index.html","primary_entity_key":"0001583648","primary_entity_name":"PALVELLA THERAPEUTICS, INC."},"word_count":84,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\n(d) Exhibits\n\n \n\nExhibit No.\n\n \n\nDocument\n\n99.1\n\n \n\n[Press Release issued by Palvella Therapeutics, Inc. on May 20, 2026*](pvla-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*Filed herewith\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nPalvella Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 20, 2026\n\nBy:\n\n/s/ Matthew Korenberg\n\n \n\n \n\n \n\nMatthew Korenberg\n\n \n\n \n\n \n\nChief Financial Officer"}